Literature DB >> 32822087

Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID-19 on Parkinson's Disease.

Cristian Follmer1.   

Abstract

Entities:  

Keywords:  Parkinson's disease; coronavirus; microbiome; neuroinflammation; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 32822087      PMCID: PMC7461175          DOI: 10.1002/mds.28231

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
Neurological manifestations in some coronavirus disease 2019 (COVID‐19) patients and the neuroinvasive potential of its causative agent, the newly discovered severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), have increasingly attracted the attention of the neuroscience community. Less obvious from a neurologic perspective is the impact of the gastrointestinal (GI) abnormalities caused by SARS‐CoV‐2 infection, notably an imbalance of the gut microbiome (dysbiosis) and intestinal inflammation, on gut‐brain axis homeostasis and central nervous system (CNS) disorders. Dysbiosis, impaired intestinal barrier integrity and colon inflammation are important factors that have been associated with the pathogenesis of Parkinson's disease (PD) and other neurological disorders. Indeed, several evidences support the hypothesis that PD first begins in the gut and then spreads to the CNS, which is corroborated by GI manifestations commonly preceding the onset of movement‐related symptoms. In this context, an important question arising is whether COVID‐19 might represent a risk factor for PD. Some patients with COVID‐19 exhibit significantly lower microbial diversity, with increased abundance of opportunistic pathogens and a decreased population of protective bacteria, which could explain the occurrence of diarrhea and colon inflammation. The entry receptor for SARS‐CoV‐2, angiotensin‐converting enzyme 2 (ACE‐2), is highly expressed in small intestinal enterocytes, in which it plays a crucial role in the composition of the gut microbiome. ACE‐2 is responsible for the renin‐angiotensin system (RAS) balance, and its dysfunction has been associated with PD pathogenesis. For instance, hyperactivation of RAS was reported to exacerbate microglia‐mediated inflammation and oxidative stress, which may contribute to degeneration of dopamine neurons in PD. In a scenario of hyperinflammation (“cytokine storm”), as reported in critically ill COVID‐19 patients, increased proinflammatory cytokines and gut dysbiosis may compromise intestinal barrier integrity, causing elevation of circulating lipopolysaccharides (LPS), which eventually might trigger microglial activation and neuroinflammation (Fig. 1). The loss of dopaminergic neurons in the substantia nigra pars compacta and the intraneuronal accumulation of aggregates of the protein α‐synuclein (aSyn), called Lewy bodies, are the main histopathological hallmarks of PD. In this respect, LPS can stimulate the formation of deposits of aSyn in enteric nerves, and, importantly, aSyn pathology in colon tissue of PD patients seems to occur prior to the onset of motor symptoms. Interestingly, treatment with a specific gut bacterium that is markedly increased in PD mouse models was sufficient to provoke selective death of dopamine neurons and motor deficits in mice, accompanied by neuroinflammation and accumulation of aggregates of aSyn in both colon and brain. Additionally, aSyn seems to play an important role in immune cell activation in the GI system (likely via a chemoattractant activity and stimulation of dendritic cell maturation), in which the expression of the protein can be induced following viral infection, potentially contributing to the formation of aSyn aggregates in enteric nervous system. Although COVID‐19 infection has not been linked so far to any specific long‐term neurological disorder, the data outlined‐above argue in favor of further investigations of the impact of SARS‐CoV‐2 infection on the incidence of PD and other neurological disorders. Viral infection‐induced gut microbiome imbalance, neuroinflammation and aSyn aggregation. Viral infection might promote gut dysbiosis and intestinal inflammation, which can lead to impaired mucosal integrity and release of LPS that, in turn, might stimulate the formation of deposits of aSyn in enteric nerves and neuroinflammation via microglial activation. Viral infection may also induce an increase in aSyn expression in enteric neurons as part of the immune response to the infection, contributing to the formation of aSyn aggregates that eventually may migrate from the intestine to the brain via the vagal nerve. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com. [Color figure can be viewed at wileyonlinelibrary.com]
  7 in total

1.  Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza.

Authors:  Silan Gu; Yanfei Chen; Zhengjie Wu; Yunbo Chen; Hainv Gao; Longxian Lv; Feifei Guo; Xuewu Zhang; Rui Luo; Chenjie Huang; Haifeng Lu; Beiwen Zheng; Jiaying Zhang; Ren Yan; Hua Zhang; Huiyong Jiang; Qiaomai Xu; Jing Guo; Yiwen Gong; Lingling Tang; Lanjuan Li
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

2.  Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.

Authors:  Kathleen M Shannon; Ali Keshavarzian; Hemraj B Dodiya; Shriram Jakate; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2012-05-01       Impact factor: 10.338

3.  A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity.

Authors:  Ethan Stolzenberg; Deborah Berry; Ernest Y Lee; Alexander Kroemer; Stuart Kaufman; Gerard C L Wong; Joost J Oppenheim; Supti Sen; Thomas Fishbein; Ad Bax; Brent Harris; Denise Barbut; Michael A Zasloff
Journal:  J Innate Immun       Date:  2017-06-27       Impact factor: 7.349

Review 4.  Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Antonio Dominguez-Meijide; Rita Valenzuela; Begoña Villar-Cheda; Ana I Rodríguez-Perez
Journal:  Mov Disord       Date:  2013-08-07       Impact factor: 10.338

5.  Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.

Authors:  Leo P Kelly; Paul M Carvey; Ali Keshavarzian; Kathleen M Shannon; Maliha Shaikh; Roy A E Bakay; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2013-11-04       Impact factor: 10.338

6.  Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice.

Authors:  Jin Gyu Choi; Namkwon Kim; In Gyoung Ju; Hyeyoon Eo; Su-Min Lim; Se-Eun Jang; Dong-Hyun Kim; Myung Sook Oh
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

7.  ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation.

Authors:  Tatsuo Hashimoto; Thomas Perlot; Ateequr Rehman; Jean Trichereau; Hiroaki Ishiguro; Magdalena Paolino; Verena Sigl; Toshikatsu Hanada; Reiko Hanada; Simone Lipinski; Birgit Wild; Simone M R Camargo; Dustin Singer; Andreas Richter; Keiji Kuba; Akiyoshi Fukamizu; Stefan Schreiber; Hans Clevers; Francois Verrey; Philip Rosenstiel; Josef M Penninger
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

  7 in total
  5 in total

Review 1.  Potential role of gut microbiota in patients with COVID-19, its relationship with lung axis, central nervous system (CNS) axis, and improvement with probiotic therapy.

Authors:  Nazanin Alibeik; Elham Pishgar; Ramin Bozorgmehr; Farshad Aghaaliakbari; Neda Rahimian
Journal:  Iran J Microbiol       Date:  2022-02

Review 2.  Gut microbiota in antiviral strategy from bats to humans: a missing link in COVID-19.

Authors:  Jia Luo; Shan Liang; Feng Jin
Journal:  Sci China Life Sci       Date:  2021-01-27       Impact factor: 10.372

Review 3.  Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease.

Authors:  Sachchida Nand Rai; Neeraj Tiwari; Payal Singh; Anurag Kumar Singh; Divya Mishra; Mohd Imran; Snigdha Singh; Etrat Hooshmandi; Emanuel Vamanu; Santosh K Singh; Mohan P Singh
Journal:  Oxid Med Cell Longev       Date:  2022-08-31       Impact factor: 7.310

Review 4.  Neurologic complications of coronavirus and other respiratory viral infections.

Authors:  Francesco Cavallieri; Johann Sellner; Marialuisa Zedde; Elena Moro
Journal:  Handb Clin Neurol       Date:  2022

Review 5.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?

Authors:  Lea Krey; Meret Koroni Huber; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2021-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.